MAPT and Alzheimer disease: The results presented here collectively indicate that a GLP1‐R agonist presents beneficial actions in the mouse and NHP brain and, along with recent clinical data, suggest that GLP1‐R activation may represent a promising new approach to help prevent abnormal tau phosphorylation, as well as IR and synapse loss, thereby contributing to protect the brains of AD patients.